In October 2026, researchers at Swiss Federal Institute of Technology Zurich (ETH Zurich) in Basel, Switzerland, unveiled an experimental electronic implant that could one day transform how type 2 diabetes is treated. Led by bioengineer Martin Fussenegger, the team published its findings in the journal Science, describing a wireless device the size of a USB stick named ECHO, short for “electrocatalytic closed-loop health optimization,” that sits just under the skin and lowers blood sugar without insulin or other drugs.
Diabetes is a chronic condition in which the body cannot properly regulate blood glucose, the sugar that fuels our cells. In type 1 diabetes, the immune system destroys the insulin-producing cells of the pancreas, while the far more common type 2 diabetes—which is often linked to obesity, inactivity, and excess energy intake over many years—develops when the body becomes resistant to insulin. Left unmanaged, high blood sugar damages blood vessels, nerves, and organs over time.
The new implant tackles the problem in an entirely new way. Instead of telling the body how to manage glucose, it removes glucose directly. The device contains a graphite wafer coated with gold nanoclusters studded with tiny platinum particles. When powered wirelessly at a medically approved frequency, this catalyst uses electricity to convert excess blood glucose into gluconate, a harmless compound the body flushes out through urine. Because that glucose is never metabolized or stored, the approach may also limit fat buildup. The system runs as a closed loop: a standard glucose sensor monitors blood sugar, and when levels spike after a meal, a smartphone or smartwatch activates the implant, which shuts off automatically once glucose returns to a safe range, preventing dangerous crashes.
The results in diabetic mice were striking. Switching on the implant brought blood glucose under control within an hour, and repeated treatment kept it regulated for six weeks, along with reduced triglycerides and lower body weight. The implant caused no inflammation, scarring, or tissue damage, and a two-week automated trial ran without any human involvement. The team even tested the catalyst against five liters of glucose solution (roughly the volume of blood in an adult human), and it cleared the sugar just as efficiently.
For the diabetic community, the implications are significant. Millions of people depend on daily insulin injections or drugs. A drug-free, electronically controlled implant integrated with everyday devices could offer hands-off glucose management. As Fussenegger put it, “If it’s possible to do this maybe every three months or up to a year, and then ‘I can forget my diabetes,’ I think people would be happy.”
Still, more research is needed. The device has not been tested in humans, and questions remain about long-term tissue compatibility and sustained catalytic activity at human scale. Even so, ECHO marks a new shift: treating diabetes not with medicine, but with electronics.
